Background: Multiple sclerosis (MS) presents with many debilitating symptoms, including urinary incontinence (UI), that physical therapy (PT) may address; UI is widely prevalent, but PT management of symptoms lacks consensus. A meta-analysis of long-term nonsurgical and nonpharmaceutical treatment options may supply this deficiency. We analyzed the current evidence for effectiveness of PT to decrease UI and improve quality of life (QOL) in people with MS.

Methods: An electronic search conducted through November 26, 2013, included the following search terms: incontinence, bladder dysfunction, urinary incontinence, multiple sclerosis, MS, physical therapy, physiotherapy, therapy, and rehabilitation. Criteria for inclusion were as follows: MS diagnosis, intervention involved PT for UI or bladder dysfunction, outcomes assessed QOL or UI, and at least a 4 of 10 on the Physiotherapy Evidence Database scale or a 2b level of evidence. Outcomes were combined across studies, and effect sizes are depicted in forest plots.

Results: Six studies met the inclusion criteria. Between-group analysis revealed statistically significant differences in incontinence episodes and QOL, but did not reach significance for functional control mechanisms (eg, electromyography data on strength of contraction, relaxation, and endurance). Incontinence leakage episodes and QOL participation improved within groups.

Conclusions: Meta-analysis indicates support for PT for minimizing incontinence compared with pretreatment and affecting incontinence and QOL more than control in people with MS. Protocols were heterogeneous regarding duration and type of PT intervention and were applied in different types of MS. Further research may reveal the most effective combination and variety of PT interventions for people with MS.

Multiple sclerosis (MS) is a chronic, degenerative disease of the central nervous system characterized by deterioration of the myelin and associated neuronal axons.1 The symptoms vary depending on the location of the lesion in the central nervous system and disease progression type. Common impairments include fatigue, ataxia, tremor, spasticity, bladder or bowel dysfunction, impaired vision, pain, cognitive disorders, dysphagia, and sexual dysfunction.1,2 MS has no clear cause and, as yet, no definite cure.3,4 

Urinary incontinence (UI), one of the common dysfunctions in MS, is also prevalent in the general population. In the United States, more than 12.6% of the general population has been diagnosed as having incontinence, with the worldwide prevalence estimated to be 115 million in 2013.57 In contrast to the non-MS population, the prevalence of UI in people with MS is 50% to 100%.8,9 If someone with MS also has vision and balance impairments, having UI poses important health and safety concerns, with an increase in fall risk while rushing to the restroom.2,3,9,10 

Physical therapy (PT) has proved to be effective in reducing the effects of UI in non-MS populations, but literature is scarce in MS.11,12 The purpose of this study was to review the existing literature regarding the effectiveness of PT in reducing UI and increasing quality of life (QOL) in people with MS.

The term UI includes both stress and urge incontinence. Stress incontinence occurs when the pelvic floor muscles (PFMs) are too weak to stop urine from leaking when coughing, laughing, or sneezing.13 Urge incontinence or overactive bladder (OAB) occurs when urine leakage is closely preceded by a powerful urge to pass urine.13 In the United Kingdom, OAB and lower urinary tract symptoms (LUTS) are predominant in the aging population.13 The LUTS include frequency, urgency, stress, and urge UI as well as voiding or obstructive complications. The annual health-care and indirect costs in 2004 in the United States for UI were $19.5 billion and for OAB were $12.6 billion,5,14 which is projected to increase to $76.2 billion in 2015.7 The most prevalent types of incontinence in MS are LUTS and OAB, affecting approximately 32% to 96% and 60% to 80%, respectively.1518 This may be underreported if, as with the general population, people with MS wait an average of 6.5 years after the onset of symptoms before seeking treatment.6,8 

The embarrassing nature of UI affects people's QOL in multiple ways, as measured using the 36-item Short Form Health Status Survey (a general health survey).10,19 The greatest deficits are seen in the subcategories of physical and social functioning, emotional health, and role limitations.10 Also, OAB was associated with depression and low self-esteem along with reduced activities of daily living (ADLs).10 With reduced activity, deconditioning may occur.2,8,10 Deconditioning has detrimental effects not only on physical structures (ie, cardiovascular and digestive systems) but also on the likelihood of depression and subjective low QOL.15,18,20 Although the impact of UI on QOL has been reported mostly in the general population, the effect in MS is likely similar.

The management of incontinence and its symptoms may be conservative or surgical. Although not all of these methods are routinely used clinically, conservative approaches described in the literature include clean intermittent self-catheterization or permanent indwelling catheters, anticholinergic agents, desmopressin, cannabinoids, complementary and alternative medicine, dorsal penile/clitoral nerve stimulation, and percutaneous posterior tibial nerve stimulation.9,21,22 Minimally invasive surgical treatments involve sacral neuromodulation,22,23 botulinum toxin injections, and augmentation cystoplasty.9 The most commonly used management methods are anticholinergic therapies, followed by clean intermittent self-catheterization or permanent indwelling catheters. Catheters are usually reserved for patients with bladder atonia or underactive bladder. The risk of infection with the use of catheters is compounded by the risk of hematuria and bladder or renal stones, as well as the hazard of urethral erosions in the long term.9 

Anticholinergic agents have limited success, lack efficacy, and are not well tolerated in the long term by people with MS. 9,24,25 Their documented adverse effects include constipation, xerophthalmia, and xerostomia. Incomplete voiding is also increased with the use of these drugs,9,24 exacerbating existing symptoms and resulting in low compliance.

A primary conservative strategy to aid with incontinence is PFM training (PFMT), developed by Dr. Arnold Kegel in 1948 for use in stress UI.13 The rationale is to increase voluntary contraction of the PFMs before events such as coughing to reduce urinary leakage.11,12 Strengthening of the PFMs is also thought to help prevent adverse perineal movement during intra-abdominal pressure changes.26,27 A possible disadvantage of overtraining the PFMs is an increase in voiding disorders.28 This can increase bladder dysfunction and decrease control of PFM relaxation, which results in problems such as hesitancy, intermittence of stream, and high postvoid residuals.27,28 Residuals of urine left in the bladder increase the risk of infection.

Neuromuscular electrical stimulation (NMES) and electromyography (EMG) biofeedback are PT interventions that teach the patient to control voluntary muscle relaxation and contraction through visual and auditory feedback. Motor learning of these voluntary muscle techniques is achieved by high session frequency.28 Burgio et al.29 studied 197 women with UI (but not MS) randomized into groups: biofeedback-assisted behavioral treatment, drug treatment, or a placebo control condition. The biofeedback group showed an 80.7% reduction in incontinence episodes, significantly different from drug treatment (68.5% reduction). Both were more effective than the placebo control condition (39.4% reduction).29 Actual evidence of changes in UI for people with MS is needed before advocating PT interventions widely.11,12 

The cost of this condition, financially and in QOL,3,25 highlights the need for a safe, well-tolerated, and effective long-term treatment that may preclude the need for surgical intervention in people with MS. Tubaro et al.,9 in a review of the management of incontinence in MS, made no discernible or definitive conclusions as treatment guidelines; standardization was hampered because of the heterogeneity of MS progression and bladder dysfunction.9,25 To our knowledge, no meta-analysis has specifically reviewed PT interventions and increased QOL related to incontinence in the MS population.

Question and Hypothesis

This review asks whether PT interventions decrease UI and improve QOL in people with MS. The null hypothesis is that PT interventions do not improve QOL or decrease UI in people with MS. It is alternatively hypothesized that PT interventions provide a statistically significant improvement in QOL and decrease UI in people with MS. The premise is that PT interventions are safer and better tolerated than drugs taken over the long term because there are no adverse effects of drug interactions with MS prescriptions,3 and treatments can be more readily adapted and tailored to each individual.

Methods

Inclusion and Exclusion Criteria

The inclusion of articles in this review was based on the following criteria: 1) participants had a diagnosis of MS; 2) participants had UI/OAB/urgency; 3) the intervention was performed by a PT, focusing on UI or bladder dysfunction; 4) the outcome measures included QOL and UI, assessed before and after intervention (for the within-group analysis) or compared with control groups (for the between-group analysis); and 6) the study was a level of evidence of 2b or better as defined by Jewell,30 or 4 of 10 on the Physiotherapy Evidence Database (PEDro) scale31 (a measure of the quality of reports of clinical trials). Articles were excluded if the interventions 1) included surgical or pharmaceutical treatment interventions, 2) focused on bowel incontinence, or 3) were not within the PT scope of practice.

Search Methods

A literature search was performed in the PubMed, Cumulative Index to Nursing and Allied Health Literature, PEDro, and Cochrane databases as well as in Google Scholar. The following search terms were used in combination and independently: incontinence, bladder dysfunction, urinary incontinence, multiple sclerosis, MS, physical therapy, physiotherapy, therapy, and rehabilitation. One researcher (V.B.) reviewed articles from the aforementioned databases for studies meeting the criteria. A recursive search of the references from relevant articles was completed, as well as a broad Google Scholar search to ensure that no relevant articles were missed. Two secondary reviewers (M.R., M.M.) verified that the selected articles met the criteria. If an article was not found on the PEDro, the PEDro scale score was calculated by the primary author (V.B.) (using the original PEDro scale score sheet)31 and was verified by a secondary reviewer (D.D.A.).

Statistical Analysis

Data regarding changes in QOL and UI were extracted from articles retrieved. The QOL and UI measures were categorized as follows: 1) participation QOL included questionnaires focused on the participation level in the patients' social environment, such as “How has urine leakage affected your participation in social activities outside of your home?” (Incontinence Impact Questionnaire-7 [IIQ-7], where 0 = not at all and 3 = greatly)32; 2) activity QOL included questionnaires focused on the effect of UI on task accomplishment, such as the amount of bother the person feels doing ADLs as a result of “frequent urination” (Urinary Distress Inventory-6 [UDI-6]: 0 = not at all bothered and 4 = greatly bothered)32; 3) objective measures of functional control mechanisms, such as EMG; and 4) recorded episodes of incontinence or leakage episodes, which includes 24-hour pad tests and bladder diaries. The reliability of the IIQ-7 and the UDI-6 have not been reported, although they have been used in multiple studies to record the impact of bladder dysfunction.9 

Individual effect sizes for each category of outcome measure were combined to calculate the grand statistics, and a 95% confidence interval was calculated. The data are presented in forest plots of within- and between-study statistics. The Q heterogeneity statistic was calculated for each meta-analysis; where Q was large (P < .05), the random effects model was used to calculate the combined effect sizes. To convert the within-group effect size to clinical units, the standard deviation before the intervention was multiplied by the grand effect size. For the between-group conversion into clinical units, the between-group pooled standard deviation was multiplied by the grand effect size.

Results

Description of the Studies

Three hundred ninety-eight records were identified through a search of electronic article databases through November 26, 2013 (Figure 1). After removing duplicates and irrelevant records, 42 full-text articles were reviewed for eligibility. Of these 42 articles, 7 met the inclusion criteria. One of these studies was a systematic review and was used as a background reference because it reported no statistical data. Six nonoverlapping articles were used for data analysis. Their PEDro scale scores were all 4 of 10 or greater (Table 1).31 The articles used in this review are outlined in the following paragraphs and are summarized in Table 2.

Figure 1.

PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-analyses) diagram outlining article selection

CINAHL, Cumulative Index to Nursing and Allied Health Literature; MS, multiple sclerosis; PEDro, Physiotherapy Evidence Database; PT, physical therapy.

Figure 1.

PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-analyses) diagram outlining article selection

CINAHL, Cumulative Index to Nursing and Allied Health Literature; MS, multiple sclerosis; PEDro, Physiotherapy Evidence Database; PT, physical therapy.

Table 1

Level of evidence of studies used in statistical analysis

Level of evidence of studies used in statistical analysis
Level of evidence of studies used in statistical analysis
Table 2

Summary of studies

Summary of studies
Summary of studies

Lucio et al.18 included 27 females with MS and LUTS in a randomized controlled trial to determine the effects of PFMT on incontinence and QOL. Participants were blindly assigned to either a control group or a treatment group, and pre-post measures of incontinence (storage, voiding, etc.) and QOL scores were recorded by blinded PTs. Treatment groups underwent PFMT with assistance from a vaginal perineometer twice a week and were instructed to perform daily exercises at home. Control group treatment consisted of only introduction of the perineometer into the vagina for 30 minutes. Outcome measures consisted of five QOL measures and subjective concerns about storage and voiding symptoms. The authors reported no differences in baseline demographic data or in compliance with session attendance between groups. The researchers found improvement in LUTS and a positive effect on QOL in women who underwent PFMT treatment.18 

Khan et al.33 conducted a randomized controlled trial studying the outcomes of bladder rehabilitation in 58 women with MS. They randomized participants into either a treatment group (n = 24) or a waitlist control group (n = 34). The treatment group received an inclusive, personalized, multidisciplinary rehabilitation program (PT, occupational therapy, speech pathology, and social work) in either an inpatient or an outpatient setting two to three times per week for 6 weeks. Thereafter, they continued with a maintenance program (stretching and home exercises) similar to the ones undertaken by the control group. Twelve months after the intervention ended, the treatment group was reassessed: QOL participation (IIQ-7) and activity (UDI-6) outcome measures showed statistically significant improvements compared with the control group. The control group was reassessed 12 months after the baseline assessment. Khan et al.33 did not allocate specific interventions to be used for the various types of bladder dysfunction seen in MS (OAB, urinary retention, detrusor sphincter dyssynergia, etc.).

Vahtera et al.34 studied the effectiveness of pelvic floor rehabilitation in people with MS. Fifty females and 30 males were divided randomly into either a control or a treatment group, with similar baseline demographic features. Treatment consisted of six electrical stimulation sessions in 21 days, and pelvic floor exercises were prescribed to do at home daily for at least 6 months. The control group received no treatment. All the participants were assessed at 3 weeks, 2 months, and 6 months. Significantly positive results were presented for the symptoms of urinary urgency, frequency, and incontinence, although no difference was noted during voluntary PFM relaxation between baseline and discharge for EMG activities. Notably, male participants responded better to the treatment than females. The authors concluded that electrical stimulation together with PFM exercises constitutes an effective treatment for LUTS in males with MS. They made no definitive conclusions regarding the effectiveness of this treatment in females.

In 2006, McClurg et al.17 conducted a randomized pilot study to compare PFMT and PFM advice (PFTA), EMG biofeedback, and NMES for bladder dysfunction in people with MS. Thirty females were randomly assigned to one of three groups: 1) PFTA, 2) PFTA and EMG biofeedback, or 3) PFTA, EMG biofeedback, and NMES. All the participants underwent 9 weeks of therapy. Outcome measures included 24-hour pad test, digital assessment of the pelvic floor (to evaluate power, endurance, number of repetitions, and number of fast contractions of the PFM, scaled from 0 to 5, with 0 being the lowest and 5 being the highest score), EMG biofeedback contraction and relaxation, voiding data, and QOL questionnaires (IIQ and UDI).17 The authors concluded that the combination of PFTA, EMG biofeedback, and NMES can reduce urinary symptoms in people with MS. In a separate study in 2008, McClurg et al.16 studied the effects of NMES on the treatment of LUTS in MS using a double-blind, placebo-controlled, randomized clinical trial. Of the 74 patients enrolled, the control group, with 26 women and 11 men, received PFMT, EMG biofeedback, and a placebo NMES. The treatment group, with 31 women and 6 men, received active NMES, PFMT, and EMG biofeedback. The results were not reported separately for men and women. Both groups were given general strategic advice regarding the maintenance of symptoms and were instructed to perform daily PFM exercises. Outcome measures were collected at baseline and at weeks 9 (end of intervention), 16, and 24. Statistical analysis between groups showed significant differences at each time point in the following test results: the 24-hour pad test, the digital assessment of PFMs (Oxford classification), and the IIQ and UDI. The EMG data regarding contraction, relaxation, and endurance showed no significant changes. McClurg et al.16,17 concluded that a combination of PFMT, NMES, and EMG biofeedback should be used as a “first-line option in alleviating some symptoms of LUTS associated with MS.”16(p231) 

De Sèze et al.24 studied transcutaneous posterior tibial nerve stimulation (TPTNS) for the treatment of OAB in MS using results from a multicenter prospective study; TPTNS is a noninvasive technique of peripheral electrical neuromodulation using surface electrodes. It modulates the sacral nerve plexus indirectly via the posterior tibial nerve, a branch of the sciatic nerve, which originates from the same segment in the spine as the nerves to the bladder and pelvic floor.35 The exact mechanisms of action are not known; however, positive results have been observed in treating OAB and UI as well as fecal incontinence.35 Seventy patients, 51 women and 19 men (final n = 66: 4 were lost to follow-up; sex was not specified) were evaluated in a single-group design, and TPTNS was applied unilaterally via electrodes behind the right medial malleolus. Patients were taught to use the device at home for 20 minutes daily for 3 months. Results of primary and secondary outcome measures were recorded at baseline, 30 days, and 90 days. Use of TPTNS statistically significantly reduced urgency and had a positive effect on QOL scores (Qualiveen questionnaire). It is unknown whether these effects were maintained long term.

Data Analysis

The combined effect sizes and 95% confidence intervals were calculated for individual studies and across studies (Table 3).36 These data are represented in a forest plot in Figure 2.37 Where Q was large (P < .05), the random effects model38 was used (Table 3).

Figure 2.

Forest plots

Combined effects for between-group (A) and within-group (B) analyses of quality of life and incontinence variables. For all the outcomes, a lower value corresponds to either a reduction in incontinence (eg, number of leakages per 24 hours) or an increase in quality of life. EMG, electromyography; F, female; GQoL, general section of Quality of Life Questionnaire; IIQ, Incontinence Impact Questionnaire; IIQ-7, Incontinence Impact Questionnaire-7; M, male; UDI, Urogenital Distress Inventory; UDI-6, Urogenital Distress Inventory-6; 24hr, 24-hour pad test.

Figure 2.

Forest plots

Combined effects for between-group (A) and within-group (B) analyses of quality of life and incontinence variables. For all the outcomes, a lower value corresponds to either a reduction in incontinence (eg, number of leakages per 24 hours) or an increase in quality of life. EMG, electromyography; F, female; GQoL, general section of Quality of Life Questionnaire; IIQ, Incontinence Impact Questionnaire; IIQ-7, Incontinence Impact Questionnaire-7; M, male; UDI, Urogenital Distress Inventory; UDI-6, Urogenital Distress Inventory-6; 24hr, 24-hour pad test.

Table 3

Summary of within- and between-group combined effect sizes and 95% CIs

Summary of within- and between-group combined effect sizes and 95% CIs
Summary of within- and between-group combined effect sizes and 95% CIs

A within-group analysis of QOL participation level was performed for the studies by Khan et al.,33 McClurg et al.,17 De Sèze et al.,24 and Lucio et al.18 Analysis of incontinence recorded (urgency and leaks per 24 hours) was performed using data from De Sèze et al.24 and McClurg et al.17  Figure 2B portrays these analyses, showing the grand effect sizes to be statistically significant for both outcome measures.

Between-group analyses for all the outcome measures are depicted in Figure 2A. Grand effect sizes were statistically significant for QOL and incontinence leakage episodes but not for functional control mechanisms (eg, EMG data on strength, relaxation, and endurance).

Harm

De Sèze et al.24 reported no adverse effects relating to the use of TPTNS, confirming findings from previous studies as to the safety of this treatment. The other studies in the present review affirmed high adherence rates and good tolerance for the treatments used.16,17,33,34 No adverse effects were reported.

Cost

There were no data available for the individual cost of each PT session for the various treatments. McClurg et al.16 suggested that with a 50% reduction in the use of medication or containment, there was a possibility of a £220.00 direct savings per individual over 6 months. All the authors reported an increase in QOL for people with MS; however, this was not quantified in financial terms.

Discussion

The aim of this review was to determine whether the current literature supports the effectiveness of PT as a treatment for UI and QOL in people with MS. Six studies met the inclusion criteria and had sufficient statistical data for a meta-analysis. Within-study analysis showed statistical significance for the incontinence leakage episodes and QOL participation level. The between-study analysis displayed significance for QOL outcomes and urinary leakage episodes. Functional control mechanisms did not reach statistical significance, although a positive difference was observed between groups. Overall, these results allow us to reject the null hypothesis that PT interventions do not improve QOL or UI in people with MS, leaving the alternative hypothesis that PT interventions present a statistically significant improvement in at least some measures of QOL and UI.

To assess the clinical relevance of the between-group results, effect sizes were converted to clinical units using the pooled standard deviation between the experimental and control groups. In terms of QOL participation level according to McClurg et al.,17 the average effect size corresponds to an IIQ score difference between groups of 32 points. On this scale, a score of 0 represents “least bother,” and 100 represents the “greatest bother.”32 Although no minimal clinically important difference has been published for this measure, maintenance of QOL in populations with a degenerative disease is advantageous. In terms of QOL activity level, the average effect size was statistically significant, and it may be clinically important, with an average difference of 43 points in the mean UDI score17 between groups. This number surpasses the anchor-based minimal important difference of −22.4 that Barber et al.39 calculated in a general population. Clinical conversion of the effect sizes for incontinence leakage episodes was not possible owing to lack of reported data.

For the within-group analysis, in terms of leakage episodes, according to McClurg et al.,17 on average patients experienced 2.1 fewer leaks per 24 hours (average of 50% decrease) after treatment with EMG, PFM advice, and NMES. In terms of participation QOL, according to McClurg et al.,17 there was an average decrease from before to after the intervention of 36 points on the IIQ. There are no minimally clinically important differences known for these outcomes in this population.

Physical therapy interventions in the included studies resulted in a direct effect on incontinence leakage episodes, as seen in the significant grand effect sizes within (−0.63) and between (−0.93) groups. The moderate effect sizes in QOL measures may indirectly result from fewer leakage episodes, but multiple factors can contribute to changes in QOL. For example, fatigue, muscle weakness, time required for ADLs, and depression can result in a decrease in QOL participation and activity levels.1 Change in any of these factors may contribute to improvements seen in this sample of participants. In addition, the decrease in UI can, in turn, reduce fatigue and depression, amplifying the effect on QOL.

The studies reported heterogeneity in the qualitative aspect of their designs. Differences in the numbers of participants and the types of interventions may have affected the results. Objective measures of functional control mechanisms (EMG/relaxation) did not reach statistical significance, possibly owing to differences in treatment frequencies (5 weeks in both studies by McClurg et al.,16,17 and only 3 weeks for the intervention in the study by Vahtera et al.34). The longer-duration treatments were associated with greater effect sizes. Other factors that may have contributed to heterogeneity include different placement of the EMG electrodes and lower adherence in the study by Vahtera et al.34 McClurg et al.16 cited high adherence values for their population.

Limitations

There were several limitations in this study that may have affected the results. 1) Although care was taken to use relevant search terms, and a variety of search engines, some literature may have been missed. 2) The sample sizes for individual studies were fairly small, which decreases the power of the individual studies, but the grand effect sizes for most of the outcomes were significant when the studies were combined. 3) Results may be limited due to the heterogeneity of MS type as well as type of incontinence in the sample populations. MS is a degenerative and unpredictable disease, hindering formulation of a standard treatment plan for everyone. A benefit of PT interventions may be that the dose, duration, and combination of treatments can be easily modified for each individual. For example, McClurg et al.17 described the amount of total EMG biofeedback treatment duration as depending on fatigue. 4) Most of the studies lacked a retention follow-up test to assess the long-term change. McClurg et al.16 observed maintenance of reduced leakage episodes, excellent adherence, and motivation until the end of their observation at 24 weeks. The authors reported that motivation and adherence have been shown to have a strong association with outcome in previous studies.16,29 

This meta-analysis included all types of PT interventions, restricting our ability to identify specific interventions that deliver the greatest effects. Physical therapy interventions do decrease incontinence and increase QOL. They are well tolerated and safe for people with MS, as no adverse or harmful effects were reported during the studies.

Future Directions

Future studies should look at specific types of MS with different forms of incontinence to determine the types of treatment that are most effective and efficient for each demographic feature. Examination of specific PT interventions with larger sample sizes could provide clinical practice guidelines for treating people with MS through conservative means. Longer follow-up studies would help determine the lasting effects of PT interventions and would shed light on the learning aspects of the treatment protocols. Data published by the National Association for Continence6 show that patients with incontinence are largely unaware of the options and benefits of PT interventions. Published data from future studies could help solidify the benefits of nonpharmaceutical or surgical interventions for this population.

Conclusion

Incontinence is a prevalent problem in the MS population and in the general public. Physical therapy interventions can help reduce the negative effects of UI by decreasing some of the symptoms and increasing QOL. Treatment protocols vary, lacking a definitive technique. With further research, specific intervention methods and outcomes could be improved.

PracticePoints
  • According to six studies meeting specified criteria, physical therapy protocols that included pelvic floor muscle training, electrical stimulation, or biofeedback were effective in reducing the frequency of urinary incontinence and in increasing quality of life (QOL) for people with MS compared with pretreatment and control groups not receiving the intervention.

  • Electromyography biofeedback did not show a significant difference in ability to relax pelvic musculature after intervention, likely because the intensity or frequency of treatment was not adequate. Longer-duration treatments were associated with greater effect sizes.

  • Future studies may determine whether physical therapy improves QOL because of the direct effect on incontinence leakage episodes or because change in urinary incontinence affects other factors, such as fatigue, time required for activities of daily living, and depression, that contribute to poorer QOL.

References

1.
Nicholas
R
,
Rashid
W.
Multiple sclerosis
.
Am Fam Physician
.
2013
;
87
:
712
714
.
2.
Coote
S
,
Hogan
N
,
Franklin
S.
Falls in people with multiple sclerosis who use a walking aid: prevalence, factors, and effect of strength and balance interventions
.
Arch Phys Med Rehabil
.
2013
;
94
:
616
621
.
3.
National Multiple Sclerosis Society website
.
http://www.nationalms-society.org. Accessed November 20, 2013
.
4.
Holland
NJ.
Urinary Dysfunction and Multiple Sclerosis: A Clinical Practice Guideline for Professionals Developed by the Multiple Sclerosis Council for Clinical Practice Guidelines
.
New York, NY
:
National Multiple Sclerosis Society
;
2013
.
5.
Markland
AD
,
Richter
HE
,
Fwu
CW
,
Eggers
P
,
Kusek
JW.
Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008
.
J Urol
.
2011
;
186
:
589
593
.
6.
National Association for Continence
.
National Association for Continence facts and statistics
. .
7.
Milsom
I
,
Coyne
KS
,
Nicholson
S
,
Kvasz
M
,
Chen
C-I
,
Wein
AJ.
Global prevalence and economic burden of urgency urinary incontinence: a systematic review
.
Eur Urol
.
2014
;
65
:
79
95
.
8.
Khan
F
,
Turner-Stokes
L
,
Ng
L
,
Kilpatrick
T.
Multidisciplinary rehabilitation for adults with multiple sclerosis
.
Cochrane Database Syst Rev
.
2007
;(
2
):
CD006036
.
9.
Tubaro
A
,
Puccini
F
,
De Nunzio
C
,
et al
.
The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review
.
Curr Urol Rep
.
2012
;
13
:
335
342
.
10.
Tubaro
A.
Defining overactive bladder: epidemiology and burden of disease
.
Urology
.
2004
;
64
(
suppl 1
):
2
6
.
11.
Temml
C
,
Haidinger
G
,
Schmidbauer
J
,
Schatzl
G
,
Madersbacher
S.
Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life
.
Neurourol Urodyn
.
2000
;
19
:
259
271
.
12.
Paltamaa
J
,
Sjogren
T
,
Peurala
SH
,
Heinonen
A.
Effects of physiotherapy interventions on balance in multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials
.
J Rehabil Med
.
2012
;
44
:
811
823
.
13.
National Institute for Health and Care Excellence
.
Urinary incontinence: introduction: a general introduction to urinary incontinence
. .
14.
Hu
T
,
Wagner
TH
,
Bentkover
DJ
,
Leblanc
K
,
Zhou
SZ
,
Hunt
T.
Costs of urinary incontinence and overactive bladder in the United States: a comparative study
.
Urology
.
2004
;
63
:
461
465
.
15.
Seth
JH
,
Sahai
A
,
Panicker
JN.
Lower urinary tract dysfunction in multiple sclerosis
.
Curr Bladder Dysfunct Rep
.
2012
;
7
:
97
104
.
16.
McClurg
D
,
Ashe
RG
,
Lowe-Strong
AS.
Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis: a double blind, placebo controlled, randomised clinical trial
.
Neurourol Urodyn
.
2008
;
27
:
231
237
.
17.
McClurg
D
,
Ashe
RG
,
Marshall
K
,
Lowe-Strong
AS.
Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study
.
Neurourol Urodyn
.
2006
;
25
:
337
348
.
18.
Lucio
AC
,
Perissinoto
MC
,
Natalin
RA
,
Prudente
A
,
Damasceno
BP
,
D'ancona
CA.
A comparative study of pelvic floor muscle training in women with multiple sclerosis: its impact on lower urinary tract symptoms and quality of life
.
Clin Sci
.
2011
;
66
:
1563
1568
.
19.
Milsom
I
,
Abrams
P
,
Cardozo
L
,
et al
.
How widespread are the symptoms of an overactive bladder and how are they managed? a population-based prevalence study
.
BJU Int
.
2001
;
87
:
760
766
.
20.
Robinson
D
,
Cardozo
L.
Overactive bladder: diagnosis and management
.
Maturitas
.
2012
;
71
:
188
193
.
21.
Sevilla
GS.
Are cannabinoids more effective than placebo in decreasing MS-related bladder dysfunction?
Br J Neurosci Nurs.
2012
;
8
:
71
78
.
22.
Minardi
D
,
Muzzonigro
G.
Lower urinary tract and bowel disorders and multiple sclerosis: role of sacral neuromodulation: a preliminary report
.
Neuromodulation
.
2005
;
8
:
176
181
.
23.
Ruud Bosch
JL
,
Groen
J.
Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients
.
Lancet
.
1996
;
348
:
717
719
.
24.
De Sèze
M
,
Raibaut
P
,
Gallien
P
,
et al
.
Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study
.
Neurourol Urodyn
.
2011
;
30
:
306
311
.
25.
Abernethy
DA
,
Weatherall
M
,
Siegert
RJ
,
Hay-Smith
EJC.
Bladder and bowel dysfunction in multiple sclerosis: a review of treatment effectiveness
.
Aust N Z Continence J
.
2007
;
13
:
81
82
,
85
,
87
89
.
26.
Dannecker
C
,
Wolf
V
,
Raab
R
,
Hepp
H
,
Anthuber
C.
EMG-biofeedback assisted pelvic floor muscle training is an effective therapy of stress urinary or mixed incontinence: a 7-year experience with 390 patients
.
Arch Gynecol Obstet
.
2005
;
273
:
93
97
.
27.
Dumoulin
C
,
Glazener
C
,
Jenkinson
D.
Determining the optimal pelvic floor muscle training regimen for women with stress urinary incontinence
.
Neurourol Urodyn
.
2011
;
30
:
746
753
.
28.
Doggweiler-Wiygul
R
,
Sellhorn
E.
Role of behavioral changes and biofeedback in urology
.
World J Urol
.
2002
;
20
:
302
305
.
29.
Burgio
K
,
Locher
J
,
Goode
P
,
et al
.
Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial
.
JAMA
.
1998
;
280
:
1995
2000
.
30.
Jewell
DV.
Guide to Evidence-Based Physical Therapy Practice
.
Sudbury, MA
:
Jones and Bartlett
;
2008
.
31.
PEDro scale
.
PEDro Physiotherapy Evidence Database website
. .
32.
Harvey
MA
,
Kristjansson
B
,
Griffith
D
,
Versi
E.
The Incontinence Impact Questionnaire and the Urogenital Distress Inventory: a revisit of their validity in women without a urodynamic diagnosis
.
Am J Obstet Gynecol
.
2001
;
185
:
25
31
.
33.
Khan
F
,
Pallant
JF
,
Pallant
JI
,
Brand
C
,
Kilpatrick
TJ.
A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis
.
J Neurol Neurosurg Psychiatry
.
2010
;
81
:
1033
1038
.
34.
Vahtera
T
,
Haaranen
M
,
Viramo-Koskela
AL
,
Ruutiainen
J.
Pelvic floor rehabilitation is effective in patients with multiple sclerosis
.
Clin Rehabil
.
1997
;
11
:
211
219
.
35.
Booth
J.
A pilot trial of transcutaneous posterior tibial nerve stimulation for bladder and bowel dysfunction in older adults in residential care
.
Institute for Applied Health Research, Glasgow Caledonian University
. .
36.
Hedges
L
,
Shymansky
J
,
Woodworth
G.
A Practical Guide to Modern Methods of Meta-analysis
.
Washington, DC
:
National Science Teachers Association
;
1989
.
37.
Clark
O
,
Djulbegovic
B.
Forest plots in Excel software (data sheet)
. .
38.
Borenstein
M
,
Hedges
L
,
Rothstein
H.
Meta-analysis: fixed effect vs. random effects model
.
In
:
Introduction to Meta-analysis
. .
39.
Barber
MD
,
Spino
C
,
Wheeler
TL.
The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire
.
Am J Obstet Gynecol
.
2009
;
200
:
e1
e7
.

Financial Disclosures: The authors have no conflicts of interest to disclose.

Author notes

From the Department of Physical Therapy and Rehabilitation Science, University of California San Francisco/San Francisco State University, San Francisco, CA, USA.